Dopavision

We are set to treat Myopia, digitally.

Dopavision is pioneering the development of digital therapeutics in ophthalmology. We are developing a game-changing therapeutic for childhood myopia which can be easily administered by using a smartphone app. Our goal is to provide a clinically validated therapeutic to help in the fight against the global myopia crisis.

Company Information

Sector
Digital Therapeutics
First Investment
Series A
Year Partnered
2021
Status
Active
Location
Berlin
CEO
Stefan Zundel